MAOB and insomnia measurement: Thus, long-term treatment (24 months) with rasagiline, a MAO-B inhibitor narrowly indicated for PD motor symptoms, or with zolpidem, a gamma-aminobutyric acid (GABA)-A receptor modulator indicated for insomnia, is strongly associated with decreased PDD incidence in two separate large cohorts (N = 195,262 in total).